recovery from cardiac disease of patients who adhere to this regimen."
Elevated antibody titers to various streptococcal products. such as the anti-streptolysin 0 (ASO) and the anti-desoxyribonuclease B (anti-DNAse B), are usually found in patients with ARF."' 12 Similarly, elevated levels of antibody to the group specific carbohydrate (A-antibody) have been reported in the majority of patients with ARF.'3 A significant observation related to the latter antibody was the finding that while the ASO and anti-DNAse B levels decline to normal within 18 months following the acute disease, the A-antibody remains elevated for several years in patients with residual rheumatic valvular disease. In contrast, persistence of the A-antibody does not occur in patients with post-streptococcal glomerulonephritis or in rheumatic patients without chronic valvular disease.'3 Based on these findings, the present study was undertaken to determine the usefulness of these antibody tests in the differentiation of rheumatic from non-rheumatic mitral valvular disease in patients lacking a history of an acute rheumatic attack.
Material and Methods

Patients
The patients included in this study are summarized in table 1 . Three groups of patients were investigated: children with mitral insufficiency (MI) during or following a well- Abbreviations: ASO = anti-streptolysin 0; Anti-DNAse B = anti-desoxyribonuclease B; A-antibody = antibody to group A streptococcal carbohydrate; ARF = acute rheumatic fever; MI = mitral insufficiency.
*Numbers in parentheses represent first and third quartile values.
documented attack of ARF (group 1); patients with congenital MI, in most cases associated with an endocardial cushion defect and cleft mitral valve (group 2); and children presenting with evidence of mitral valve disease (most commonly asymptomatic MI) in the absence of history of ARF and lacking features suggestive of an endocardial cushion defect (group 3). Each of the 47 patients in group 1 presented with an acute illness clearly fulfilling the modified Jones criteria'4 for the diagnosis of ARF. All patients in group 1, including those studied during the acute stage of ARF (group la), as well as those investigated 18-36 months after ARF (group lb), manifested MI at the time of study. Several patients also had murmurs.of aortic valvular insufficiency (AI). Group lb consisted of 13 patients included in group la plus four other patients who had been followed prospectively after their acute episode of ARF. Initial sera were not available from these latter four patients, although each had had an elevated ASO level. All 17 patients in group lb were selected because their ASO and anti-DNAse B titers had declined to within 0.1 log above the upper limit of normal during the follow-up period of 18-36 months after their acute attack. The remaining patients of group la were excluded from category lb because their acute attacks occurred less than 18 months ago (15 patients), because follow-up sera were not available (13 patients) , or because the ASO and/or anti-DNAse B titers were still 0.2 log or greater above the upper limits of normal 18-36 months after ARF (6 patients).
The patients in group 2 include 26 children with con- evidence of ARF who were referred for the evaluation of possible rheumatic heart disease because of the auscultatory findings of mitral valve disease, most commonly isolated MI. In these patients, almost all of whom were asymptomatic, history of an illness suggestive of an attack of ARF could not be elicited, and the electrocardiographic and clinical findings characteristic of an endocardial cushion defect or other specific anomaly were not present. Several of the patients were found to have AI also, while five patients had mitral stenosis, either isolated or in conjunction with MI and/or AI, discovered as early as four years of age.
Sera
Serum specimens obtained from the patients in groups 1-3 were handled aseptically and stored at -10C until the time of assay. Antibody assays were performed on proportionate numbers of sera from each of the study groups and from the control group (vide infra).
Antibody Determinations ASO and anti-DNAse B titers were measured by the micro methods previously described.'5 '6 The serum dilution scheme for the ASO and anti-DNAse B titers was based on a logarithmic scale, with 0.1 log separating each of the consecutive tube dilutions. The values obtained for ASO and anti-DNAse B titers were expressed as logs of antibody titers. A-antibody levels were determined by the radioimmune precipitin assay,'3 and were expressed as the fraction of C'4-A-carbohydrate bound by 0.2 cc whole serum and precipitated at half-saturation with ammonium sulfate. The antibody scale for this test spans from 0.00 to 1.00 "units"'
with the antibody levels of various sera differing by multiples of 0.01 units.
Normal Antibody Levels
The upper limits of normal for A-antibody, ASO Abbreviations: ASO = anti-streptolysin antibody to group A streptococcal carbohyc randomly obtained throughout the calendar year. The upper limit of normal was defined as that antibody titer or level exceeded by no more than 20% of the normal children."
Results
Normal Antibody Values
As defined above, the upper limits of normal for the three streptococcal antibodies studied were found to be: 200 for ASO (log of titer = 2.3), 320 for antiDNAse B (log of titer = 2.5), and 0.60 for the A-antibody. These values are comparable to those obtained in other geographic locations. '2 13 Antibody Titers of Patients of The median log ASO and anti-DNAse B titers and the median A-antibody levels (with first and third quartile values) for the study groups are presented in table 1. Antibody Titers of Patients with ARF and Chronic Inactive Rheumatic Heart Disease (Group 1). As expected, the anti-streptococcal antibody levels of 47 patients with ARF in association with MI (group la) 0; anti-DNAse B = anti-desoxyribonuclease B; A-antibody = Irate; MI = mitral insifficiency.
were markedly elevated (table 1) . Each ARF patient manifested an A-antibody level greater than 0.60. With the exception of two subjects with normal ASO titers and three patients with normal anti-DNAse B titers, the ARF patients demonstrated elevated ASO and anti-DNAse B levels. Streptococcal antibody titers for serum samples obtained [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] months following well-documented ARF with MI are plotted in figure 1. Although each patient in this group had essentially normal ASO and anti-DNAse B titers at the time of study, 15 of the 17 patients (88%) manifested persistence of elevated levels of A-antibody. Comparison of ASO titers of groups la and lb, as expected, revealed significantly higher titers among group la (P < 0.001). Likewise, higher anti-DNAse B titers were found among the group la patients (P < 0.001). In contrast, no significant difference in A-antibody level was observed between the two rheumatic groups studied during the acute stage of ARF as well as 18-36 months following ARF (P > 0.05). These prospective findings confirm the previously reported retrospective data13 and suggest that an elevated A-antibody level convalescent from recent streptococcal infection, 17 and probably reflected recent streptococcal infection.
Discussion
The difficulty in clinically differentiating rheumatic from non-rheumatic mitral valve disease has resulted in the management of children with mitral valve disease of unknown etiology in a fashion identical to that of patients with unequivocal rheumatic heart disease. While the benefits of a prophylactic regimen for patients with rheumatic heart disease have been well established, there appears to be little advantage of such a regimen to the patient with non-rheumatic heart disease. In of elevated A-antibody among patients with chronic rheumatic valvular heart disease. ' ARF. These findings suggest that the use of the above criterion yielded no "false positives" and only a rate of 12% "false negatives" in the differentiation of rheumatic from non-rheumatic chronic mitral disease. Previous retrospective studies of adult patients with chronic inactive rheumatic heart disease have demonstrated elevated A-antibody levels in 58% of patients studied as long as 10 to 25 years after their presumed last attack of ARF.13 This study had certain limitations including its retrospective nature, the documentation of the acute attacks of ARF in many of the patients only by history, and the fact that some of the patients included had pure aortic regurgitation, a finding now recognized to be infrequently due to rheumatic heart disease.4 These factors could result in the inclusion of some nonrheumatic individuals which, with the small number of patients studied, could produce an apparent lower frequency of elevated A-antibody in patients with chronic inactive rheumatic mitral disease. Although the present data do not allow for conclusions regarding the applicability of the A-antibody test for differentiating rheumatic from non-rheumatic mitral valve disease beyond 36 months after ARF, prospective studies now being carried out should provide data regarding the usefulness of this test at longer intervals after ARF.
Circulation. Volume 50, December 1974 Recent studies by Burch and Giles provide data suggesting that infectious agents other than the group A streptococcus may be etiologically related to the pathogenesis of acquired valvular heart disease.' Convincing evidence exists that Coxsackie viruses in particular are capable experimentally of producing chronic valvular lesions resembling rheumatic heart disease among cynomolgus monkeys, although the significance of such agents with respect to acquired valvular heart disease in humans is unclear. 20 The finding that a large percentage of patients with mitral disease of unknown etiology may have nonrheumatic disease agrees with the experience of other investigators who have assessed the frequency of nonrheumatic mitral disease by other parameters. Using cineangiocardiographic criteria, Wexler et al. found that 43% of a series of adult patients with MI had nonrheumatic heart disease, with subsequent confirmation by surgical and pathologic examination.3 Several pathologic studies have confirmed the frequency of non-rheumatic valvular heart disease. In a large autopsy series of adults with chronic valvular disease, Roberts concluded that 24% of patients with isolated mitral valve disease had non-rheumatic heart disease, based upon pathologic examination. 4 Likewise, the fact that congenital mitral valve disease is not exceptionally uncommon was emphasized in the recent report by Davachi et al. summarizing the pathologic findings of mitral valve lesions in 55 infants with congenital disease.5 Other clinical studies also have noted that non-rheumatic mitral disease is frequently encountered. In their review article Selzer and Cohn refer to the fact that pure mitral regurgitation is most often non-rheumatic in origin. 6 The frequency of solitary congenital MI, including the ballooning mitral valve syndrome, was commented upon in a recent editorial by Vlad, who noted that in children it ranks second in frequency only to rheumatic mitral valve disease.7
The findings in the present study are in agreement with the above studies and tend to support the concept advanced in these reports that many patients may have mitral disease of non-rheumatic etiology. The streptococcal antibody tests used in this study, together with electrocardiographic, roentgenographic and clinical data, may be useful in distinguishing between rheumatic and non-rheumatic mitral valve disease in the majority of patients whose disease is of obscure etiology.
